Bibliography

Patent Blue V – Bibliography

See & make the right choice

(1) NATOMIMAGES – Callimedia.

(2) American Joint Committee on Cancer (AJCC), Breast cancer Staging , 7th Edition, 2009, https://cancerstaging.org/ references-tools/ quickreferences/Documents/BreastMedium.pdf

(3) Nos C. et al., Macroscopic Quality Control Improves the Reliability of Blue Dye-Only Sentinel Lymph node Biopsy in Breast Cancer, Annals of Surgical Oncology, 2003, 10(5): 525-530.

(4) Nos C. et al., Sentinel Lymph Node Detection for Breast Cancer: Which Patients Are Best Suited for the Patent Blue Dye Only Method of Identification, Annals of Surgical Oncology,2001,8(5): 438-443.

(5) Borgstein P.J. et al., Functional Lymphatic Anatomy for Sentinel Node Biopsy in Breast Cancer, Ann Surg., 2000, 232(1): 81–89.

(6) Senkus E. et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, 2015, 26: v8–v30.

(7) NBOCC, Recommendations for staging and managing the axilla, 2011, https://guidelines.canceraustralia.gov.au/guidelines/axilla_early/

(8) ASCO, Lyman G. et al., Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer Update, 2016, http://www.asco.org/practice-guidelines/quality-guidelines/guidelines/breast-cancer#/9801

(9) Schwartz G.F. et al. Clinical practice guidelines for the use of axillary sentinel lymph node biopsy in carcinoma of the breast: current update, Breast J., 2004,10(2):85-88.

(10) Vidal-Sicart S. et al. Review Article: Sentinel Node Mapping for Breast Cancer: Current Situation, Journal of Oncology, 2012, Article ID 361341,1-7.

(11) Association of Breast Surgery at BASO, Association of Breast Surgery Guidelines Use of Blue dye for SLNB, 2009.

(12) HAS, Note de cadrage, Place de la technique du ganglion sentinelle dans la stratégie diagnostique de l’envahissement ganglionnaire d’un cancer du sein à un stade précoce, 2011, p. 21.

(13) Van la Parra R.F.D. et al., A prospective validation study of sentinel lymph node biopsy in multicentric breast cancer: SMMaC trial, EJSO, 2014, 40: 1250-1255.

(14) Elmadahm A. A. et al., Identification of the sentinel lymph node in the SNAC-1 trial, Royal Australasian College of Surgeons, ANZ J Surg., 2015, 85: 58–63.

(15) Jean-Francois Rodier, et al., Prospective Multicentric Randomized Study Comparing Periareolar and Peritumoral Injection of Radiotra¬cer and Blue Dye for the Detection of Sentinel Lymph Node in Breast Sparing Procedures: FRANSENODE Trial, Journal Of Clinical Oncology,2007, 25(24): 3664- 3669.

(16) Barthelmes L. et al., Adverse reactions to patent blue V dye – The NEW START and ALMANAC experience, EJSO, 2010, 36: 399-403.

(17) Mansel RE. et al., Randomized Multi-center Trial of Sentinel Node Biopsy Vs Standard Axilliary Treatment in Operable Cancer: the ALMANAC Trial, JNCI, 2006, 98(9): 599-609.

(18) Mirjam CL Peek , et al. Is blue dye still required during sentinel lymph node biopsy forbreast cancer, Ecancer, 2016,10:674.

(19) Classe J. M. et al., Cost comparison of axillary sentinel lymph node detection and axillary lymphadenectomy in early breast cancer.
A national study based on a prospective multi-institutional series of 985 patients ‘on behalf of the Group of Surgeons from the French Unicancer Federation,, Annals of Oncology,2011,23: 1170–1177.

We use cookies to improve your website experience and to gain insights into our websites’ users and traffic to make it even better. By continuing your navigation on our site without modifying the setting of your cookies, you accept the use of cookies. OKFind out more